Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype
暂无分享,去创建一个
Yi Su | Shruti Mishra | Brian A. Gordon | David M Holtzman | J. Morris | D. Holtzman | Yi Su | Tyler Blazey | Carlos Cruchaga | T. Benzinger | Shruti Mishra | Brian A Gordon | Tammie L S Benzinger | John C Morris | Carlos Cruchaga | Tyler M Blazey | Tyler M. Blazey | B. Gordon | J. Morris | J. Morris
[1] Christopher J. Owen,et al. Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease , 2016 .
[2] C. Jack,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.
[3] M. Perola,et al. Cortical ¹¹C-PIB uptake is associated with age, APOE genotype, and gender in "healthy aging". , 2014, Journal of Alzheimer's disease : JAD.
[4] Paul M. Thompson,et al. The apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging , 2014, Neurobiology of Aging.
[5] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[6] Chengjie Xiong,et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease , 2016, Annals of neurology.
[7] P. Vemuri,et al. Brain β-amyloid load approaches a plateau , 2013, Neurology.
[8] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[9] Y. Kokubo,et al. [Apolipoprotein E]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[10] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[11] P. Murali Doraiswamy,et al. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth , 2013, NeuroImage.
[12] D. Holtzman,et al. Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins , 2017, Journal of Lipid Research.
[13] H. Soininen,et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ϵ4 allele , 1995, Neurology.
[14] F. Lalonde,et al. Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women , 2001, Neurology.
[15] Daniel Bandy,et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease , 1998, Annals of neurology.
[16] Norbert Schuff,et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, NeuroImage.
[17] C. Jack,et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.
[18] A. Rahmim,et al. The ARIC-PET amyloid imaging study , 2016, Neurology.
[19] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[20] G. Chételat,et al. Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan , 2014, Neuropsychology Review.
[21] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[23] Matthew L Senjem,et al. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. , 2015, JAMA neurology.
[24] John C. Morris,et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure , 2017, NeuroImage.
[25] C. Rowe,et al. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[26] Carole Dufouil,et al. No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. , 2005, NeuroImage.
[27] C. Jack,et al. Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort , 2010, Neurobiology of Aging.
[28] Denise C. Park,et al. &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.
[29] Tianzi Jiang,et al. Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults , 2010, Neuroscience Letters.
[30] J. Karlawish,et al. The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.
[31] Guojun Bu,et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[32] Brian A. Gordon,et al. The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia , 2015, NeuroImage: Clinical.
[33] W. Klunk,et al. Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease , 2010, Biological Psychiatry.
[34] Chengjie Xiong,et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. , 2015, JAMA neurology.
[35] Keith A. Johnson,et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.
[36] Jerry L Prince,et al. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts , 2015, Neurobiology of Aging.
[37] Tyler Blazey,et al. Regional variability in Alzheimer's disease biomarkers. , 2014, Future neurology.
[38] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[39] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[40] Andrei G. Vlassenko,et al. Quantitative Analysis of PiB-PET with FreeSurfer ROIs , 2013, PloS one.
[41] Keith A. Johnson,et al. Partial volume correction in quantitative amyloid imaging , 2015, NeuroImage.
[42] Richard J. Caselli,et al. Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates , 2007 .
[43] Holly Soares,et al. Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.
[44] A. Evans,et al. Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] A. Bush,et al. The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update , 2016, Journal of Molecular Neuroscience.
[46] C. Jack,et al. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern , 2015, Alzheimer's & Dementia.
[47] Michael Weiner,et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.
[48] Hiroaki Kazui,et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E ε4 allele , 2002 .
[49] John K. Kruschke,et al. Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan , 2014 .
[50] Sebastien Ourselin,et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease , 2013, Neurology.
[51] Yi Su,et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.
[52] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[53] C. Jack,et al. Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.
[54] Lewis H Kuller,et al. In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects , 2013, Annals of neurology.
[55] Dorota Kurowicka,et al. Generating random correlation matrices based on vines and extended onion method , 2009, J. Multivar. Anal..
[56] N. Craddock,et al. Protection against Alzheimer's disease with apoE ∈2 , 1994, The Lancet.
[57] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[58] Cindee M. Madison,et al. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[59] D. Rubin,et al. Inference from Iterative Simulation Using Multiple Sequences , 1992 .
[60] Lisa A. Weissfeld,et al. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches , 2013, NeuroImage.
[61] P. Murali Doraiswamy,et al. Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network. , 2014, Radiology.
[62] Mayo Clinic,et al. PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .
[63] Charles DeCarli,et al. APOE-ε4 is associated with less frontal and more medial temporal lobe atrophy in AD , 1999, Neurology.
[64] Shravan Vasishth,et al. Bayesian linear mixed models using Stan: A tutorial for psychologists, linguists, and cognitive scientists , 2015, 1506.06201.
[65] N. Schuff,et al. Age effects on atrophy rates of entorhinal cortex and hippocampus , 2006, Neurobiology of Aging.
[66] Michael W. Weiner,et al. APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years , 2014, Neurobiology of Aging.
[67] S. Resnick,et al. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype , 2000, Neurology.
[68] Nick C Fox,et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.
[69] S. Wilton,et al. Apolipoprotein E and Alzheimer's disease , 1995 .
[70] A M Dale,et al. Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[71] R. Castellani,et al. Alzheimer disease. , 2010, Disease-a-month : DM.
[72] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[73] Nick C Fox,et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment , 2007, Neurology.
[74] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[75] W. Jagust,et al. Apolipoprotein E, Not Fibrillar β-Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging , 2012, The Journal of Neuroscience.
[76] Andrei G. Vlassenko,et al. Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.
[77] Magda Tsolaki,et al. Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. , 2010, Journal of Alzheimer's disease : JAD.
[78] Christopher A. Hostage,et al. Dissecting the Gene Dose-Effects of the APOE ε4 and ε2 Alleles on Hippocampal Volumes in Aging and Alzheimer’s Disease , 2013, PloS one.
[79] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[80] A. Gelman,et al. Stan , 2015 .
[81] Abraham Z. Snyder,et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume , 2004, NeuroImage.
[82] E G Tangalos,et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease , 1998, Annals of neurology.
[83] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[84] D. Y. Lee,et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.
[85] Jiqiang Guo,et al. Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.
[86] Hiroaki Kazui,et al. Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer’s disease , 2001, Neurology.
[87] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[88] Agatha D. Lee,et al. Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. , 2011, Journal of Alzheimer's disease : JAD.
[89] J. Kaye,et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.
[90] Hiroaki Kazui,et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. , 2002, Annals of neurology.
[91] Carole Dufouil,et al. No ɛ4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects , 2005, NeuroImage.
[92] Margaret A. Pericak-Vance,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .
[93] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[94] Keith A. Johnson,et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease , 2013, Neurobiology of Aging.
[95] J. Morris,et al. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.
[96] R. Bhadra,et al. NIH Public Access , 2014 .
[97] M Schwaiger,et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease , 2009, Neurology.
[98] Norbert Schuff,et al. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data , 2010, Alzheimer's & Dementia.
[99] Jerry L. Prince,et al. Individual estimates of age at detectable amyloid onset for risk factor assessment , 2016, Alzheimer's & Dementia.